Resolution Therapeutics Welcomes New CFO and CBO as It Advances Innovative Therapies

Exciting Leadership Changes at Resolution Therapeutics

Resolution Therapeutics, a pioneering clinical-stage biopharmaceutical firm focused on innovative regenerative therapies, has recently announced significant leadership appointments in a move that aims to bolster its strategic direction and operational excellence. Lucy Singah has been appointed as the new Chief Financial Officer (CFO), and Daniel Kennedy has stepped into the role of Chief Business Officer (CBO). These strategic additions come at a crucial juncture for the company, particularly following the recent announcement regarding the successful dosing of the first patient with RTX001 in the ongoing Phase I/II EMERALD trial.

Strengthening the Executive Team

Dr. Amir Hefni, CEO of Resolution Therapeutics, expressed enthusiasm about the new appointments, stating, "We are delighted to welcome Lucy and Dan to our leadership team at this exciting time in the Company's journey. With the first patient dosed with RTX001, we look forward to harnessing their experience to enhance our mission of transforming patient outcomes through innovative regenerative macrophage therapy."

Lucy Singah - Chief Financial Officer

Lucy Singah brings over two decades of extensive experience in corporate and strategic finance across both U.S. and UK markets. Before joining Resolution, Lucy was the CFO at Echopoint Medical, where she played a pivotal role in financial planning and development during key stages of the company. Her track record includes significant accomplishments in financial strategy and investor relations, with expertise garnered from previous roles at Amazonia Impact Ventures and GSK, among others. At GSK, Lucy held various roles in Mergers & Acquisitions and as a leader in investor relations.

Upon her appointment, Lucy shared her enthusiasm, stating, "I am honored to join Resolution at such a pivotal stage of its development. I look forward to leveraging my skills to help advance the company’s financial goals and to furthering the clinical journey of RTX001."

Daniel Kennedy - Chief Business Officer

Daniel Kennedy, with over 20 years of business development experience in the pharmaceutical and biotech sectors, is also set to make significant contributions to Resolution's growth. His previous position as Vice President of Business Development at Immunocore allowed him ample opportunities to forge lucrative partnerships and manage key licensing agreements. He gained valuable experience leading business development at Achillion Pharmaceuticals, which was notably acquired by Alexion Pharmaceuticals for nearly $1 billion.

Daniel expressed his pride in joining Resolution, saying, "I am excited to be part of a company with a distinguished approach to treating inflammatory and fibrotic diseases. I aim to support the company’s growth as we enroll and treat patients, driving our mission forward."

A New Era for Resolution Therapeutics

The appointments of Lucy Singah and Daniel Kennedy significantly enhance the leadership team at Resolution Therapeutics at a time marked by rapid progress in clinical trials, particularly the Phase 1/2 EMERALD study, which evaluates the efficacy of RTX001, a cutting-edge engineered autologous regenerative macrophage therapy designed to treat end-stage liver disease. This innovative therapy is utilizing mRNA technology to boost the macrophages' natural regenerative capabilities.

As the company prepares to host an important RD webinar on September 17, 2025, which will include esteemed clinical hepatologists sharing insights on their research and the advancements surrounding RTX001, these leadership appointments are viewed as critical to the company’s future success and alignment with its mission to enhance patient care.

In summary, the addition of Lucy Singah and Daniel Kennedy to the Resolution Therapeutics team represents a strategic enhancement to the company’s capabilities, enabling it to better navigate the complexities of the biopharmaceutical industry while staying committed to its vision of innovation in regenerative therapies.

For more information on Resolution Therapeutics and its initiatives, visit Resolution Therapeutics Website and engage with them on LinkedIn.